- IMT is currently offering private equities, investment funds, venture capitals and professional investors an investment opportunity to participate in its early stage of commercial development of anti-IgD mAb.
- IMT aims to raise US$19 million in capitals funding to create and produce the humanized of anti-IgD mAb – a tangible asset of IMT – that is ready to proceed to human clinical trials within 2-4 years. The capital funding will be allocated to create, produce and validate a humanized anti-IgD mAb with required therapeutic features for human clinical trials leveraging IMT’s leading research insights, knowledges and IP on the biology of IgD and anti-IgD antibody bioassays.
- IMT currently offers a 10-20% equity in IMT plus 2 Board seats (Co-Founder, CEO or CFO) for US$19 million in capital funding to generate and produce a humanized anti-IgD mAb product.
- IMT is also seeking collaborative and strategic partnerships with biotech and pharmaceutical companies with business focuses and interests in the commercialization of therapeutic mAb for immune-mediated conditions.
- For further inquiries, please contact IMT.
IgD Mab Technology (IMT) 